摘要
目的观察益气活血方治疗急性加重期慢性阻塞性肺疾病(COPD)的临床疗效。方法首先将符合诊断标准的患者分为男、女两组,每组60例,按照入组时间先后顺序,男、女两组中单号入治疗组,双号入对照组。对照组60例,采用吸氧联合西药治疗;治疗组60例,在对照组治疗基础上加用益气活血方治疗。两组均以治疗2周为1个疗程,比较两组治疗前后第一秒用力呼气容积占预计值百分比(FEV1%),并评价中医症状积分,判定疗效。结果治疗后治疗组中医症状积分为(6.3±5.3)分,对照组中医症状积分为(9.8±7.2)分,两组比较,差异有统计学意义(P<0.05);治疗组有效27例,对照组有效15例,两组比较,差异有统计学意义(P<0.01)。结论益气活血方治疗急性加重期慢性阻塞性肺疾病,针对病因病机,结合患者多为老年人的特点,遣方用药,取得了良好的临床疗效。
Objective To observe the clinical efficacy of yiqi huoxue formula on chronic obstructive pulmonary disease（COPD）at acute aggravation stage.Methods The patients who were complied with the diagnostic criteria were divided into a male group and a female group,60 cases in each one.In accordance with the inclusive sequence,of the cases in male group and female group,those with single number in the sequence were classified into a trial group and those with double number were into a control group.60 cases in control group were treated with oxygen combined with western medicine therapy.60 cases in trial group were treated with yiqi huoxue formula supplemented on the basis of the treatment as control group.The cases in either group were treated for 2 weeks as 1 session.The forced expiration volume in one second/predicted value（FEV1%）was compared before and after treatment between two groups.The symptom score of traditional Chinese medicine（TCM）and the efficacy were assessed.Results After treatment,the symptom score of TCM was（6.3±5.3）score in treatment group and was（9.8±7.2）score in control group,presenting statistical significant difference in comparison（P0.05）.27 cases were effective in treatment and 15 cases in control group,indicating statistical significant difference in comparison（P0.05）.Conclusion Yiqi huoxue formula achieves a good clinical efficacy on COPD at acute aggravation stage,concerning to its etiology and pathogenesis and in association with the characteristics of the elderly.
出处
《世界中西医结合杂志》
2011年第12期1052-1053,1063,共3页
World Journal of Integrated Traditional and Western Medicine
关键词
益气活血复方
慢性阻塞性肺疾病
临床观察
Yiqi huoxue formula
Chronic obstructive pulmonary disease（COPD）
Clinical observation
